- Home
- TRX vs ADAG Comparison
TRX vs ADAG Comparison
Compare TRX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRX | ADAG |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.9M | 84.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRX | ADAG |
|---|---|---|
| Price | $1.00 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.25 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.8M | 53.1K |
| Earning Date | 01-13-2026 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $57,613,000.00 | $103,204.00 |
| Revenue This Year | $93.43 | $6,983.06 |
| Revenue Next Year | $44.56 | $36.05 |
| P/E Ratio | $394.10 | ★ N/A |
| Revenue Growth | ★ 39.98 | N/A |
| 52 Week Low | $0.27 | $1.30 |
| 52 Week High | $1.02 | $3.16 |
Technical Indicators
Market Signals| Indicator | TRX | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 74.69 | 48.48 |
| Support Level | $0.91 | $1.76 |
| Resistance Level | $0.89 | $1.93 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 89.89 | 48.94 |
Price Performance
Historical ComparisonAbout TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.